A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
Merck

Protocol Number
Merck MK-3475-029

To Learn More Call
(201)-510-0950